Targeted‐nanoliposomal combretastatin A4 (CA‐4) as an efficient antivascular candidate in the metastatic cancer treatment

• Published in: Journal of cellular physiology Vol. 234; no. 9; pp. 14721 - 14733
• Main Authors: Nik, Maryam Ebrahimi, Momtazi‐Borojeni, Amir Abbas, Zamani, Parvin, Navashenaq, Jamshid Gholizadeh, Iranshahi, Mehrdad, Jaafari, Mahmoud Reza, Malaekeh‐Nikouei, Bizhan
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2019
• Subjects: Angiogenesis inhibitors; antiangiogenesis; Antiangiogenic agents; Antiangiogenics; Bioavailability; Cancer; Cancer therapies; combretastatin A4; Drug development; Formulations; Liposomes; Metabolism; Metastases; Migration; nanoliposome; Side effects; Therapy; Tumors; nanoliposome; cancer; antiangiogenesis; combretastatin A4

A number of antiangiogenic drugs have been approved by the Food and Drug Administration which are used in cancer therapy, and variety of other agents in several stages of clinical development or in preclinical assessment. Among these, combretastatin A4 (CA‐4) is an under‐researched inhibitor of angi...